These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22444679)

  • 1. Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib.
    Kuchar M; Oliveira MC; Gano L; Santos I; Kniess T
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2850-5. PubMed ID: 22444679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2.
    Caballero J; Muñoz C; Alzate-Morales JH; Cunha S; Gano L; Bergmann R; Steinbach J; Kniess T
    Eur J Med Chem; 2012 Dec; 58():272-80. PubMed ID: 23131541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.
    Kirk NS; Bezos A; Willis AC; Sudta P; Suksamrarn S; Parish CR; Ranson M; Kelso MJ
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1813-6. PubMed ID: 26912111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and radiopharmacological investigation of 3-[4'-[(18)F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor.
    Kniess T; Bergmann R; Kuchar M; Steinbach J; Wuest F
    Bioorg Med Chem; 2009 Nov; 17(22):7732-42. PubMed ID: 19822433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.
    Yang TH; Lee CI; Huang WH; Lee AR
    Molecules; 2017 May; 22(6):. PubMed ID: 28561780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential inhibitors of angiogenesis. Part II: 3-(azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones.
    Braud E; Duflos M; Le Baut G; Renard P; Pfeiffer B; Tucker G
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):253-7. PubMed ID: 14506916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
    Maskell L; Blanche EA; Colucci MA; Whatmore JL; Moody CJ
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1575-8. PubMed ID: 17254788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
    J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
    Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
    J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
    Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
    Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
    Levashova Z; Backer M; Hamby CV; Pizzonia J; Backer JM; Blankenberg FG
    J Nucl Med; 2010 Jun; 51(6):959-66. PubMed ID: 20484434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.
    Majumder S; Piguet AC; Dufour JF; Chatterjee S
    Eur J Pharmacol; 2013 Apr; 705(1-3):86-95. PubMed ID: 23454556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution of 99mTc-sunitinib as a potential radiotracer for tumor hypoxia imaging.
    Sakr TM; El-Safoury DM; Awad GA; Motaleb MA
    J Labelled Comp Radiopharm; 2013 Jun; 56(8):392-5. PubMed ID: 24285479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.
    Mamat C; Mosch B; Neuber C; Köckerling M; Bergmann R; Pietzsch J
    ChemMedChem; 2012 Nov; 7(11):1991-2003. PubMed ID: 23042640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
    Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery.
    Ishii S; Okamoto Y; Katsumata H; Egawa S; Yamanaka D; Fukushima M; Minami S
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):359-66. PubMed ID: 23324994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
    Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
    Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
    Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
    Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.